Clinical Trial Update: ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports a completed Phase 1/2 study of ALT-803 in combination with nivolumab for pretreatment, advanced or metastatic non-small cell …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ALT-803 (Interleukin-15 super-agonist)
• nivolumab (nivolumab)

Snippet

Sponsor: Medical University of South Carolina | Conditions: Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-02-17